Study to Improve Survival Among HIV-Exposed Infants in Botswana
Information source: Harvard School of Public Health
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections; Neutropenia; Anemia
Intervention: cotrimoxazole prophylaxis (Drug); cotrimoxazole placebo (Drug); exclusive breastfeeding until 6 months of age (Behavioral); breastfeeding for 12 months (Behavioral)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: Harvard School of Public Health Official(s) and/or principal investigator(s): Shahin Lockman, MD, MS, Principal Investigator, Affiliation: Harvard School of Public Health Roger L Shapiro, MD, MPH, Principal Investigator, Affiliation: Harvard School of Public Health
Summary
The purpose of this study is to find ways to improve infant health and survival among
infants whose mothers are HIV-infected but who do not themselves have HIV.
Clinical Details
Official title: A Randomized Study of Cotrimoxazole Prophylaxis and Longer Breastfeeding Duration to Improve Survival Among HIV-Exposed Infants in Botswana
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: Survival
Secondary outcome: HIV-free SurvivalSafety of CTX prophylaxis Morbidity and mortality
Detailed description:
As improved MTCT prevention interventions reduce the number of HIV-infected infants in the
antepartum and peripartum periods, interventions to improve HIV-free survival among
HIV-uninfected infants are needed. Morbidity and mortality are increased among
HIV-uninfected infants born to HIV-infected mothers, and reduced infant survival among
HIV-exposed infants may lead to as many deaths as HIV infection itself. In Botswana, the use
of formula feeding or shorter breastfeeding may worsen the problem of early infant mortality
among HIV-exposed infants.
The study will enroll pregnant or postpartum HIV-1-infected women, and their HIV-uninfected
infants in Botswana. At 2-4 weeks of age, live HIV-uninfected infants will be randomized to
receive either double-blinded cotrimoxazole (CTX) or placebo from 2-4 weeks through 15
months. In addition, breastfeeding (BF) infants will be randomized to BF until either 6 or
12 months of age. Children will be followed prospectively until 18 months of age. The
primary endpoint will be survival at 18 months comparing all infants in the CTX vs. placebo
arms, and by randomized duration of BF among those BF at randomization. Secondary endpoints
will evaluate survival and morbidity/mortality at 12 and 15 months; HIV-free survival to 18
months; and the safety of CTX prophylaxis. Secondary observational objectives include
comparing MTCT and mortality by initial feeding method (formula feeding or any BF > 1
month), and an analysis of maternal characteristics as predictors for initial feeding choice
and HIV-free survival. All women and infants will receive standard antenatal and peripartum
prophylaxis from the Botswana government for MTCT prevention (PMTCT), and will choose a
feeding method with counseling. Breastfeeding infants will receive infant nevirapine (NVP)
prophylaxis or will be protected from MTCT by the use of maternal HAART.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- HIV-infected women, > 26 weeks gestation and < 34 days postpartum.
- Women must be ¬> 18 years of age and willing/able to sign informed consent.
- Women and infants must be able to follow up regularly at a study clinic through 18
months postpartum.
- For Feeding Randomization Only: Women must be willing to breastfeed for up to 12
months, and to stop at 6 months, depending upon their feeding assignment.
Exclusion Criteria:
- Antepartum women: Known infant anomalies resulting in a high probability that the
infant will not survive to 18 months.
- Postpartum women: Known HIV-infected infant, or infant medical condition making
survival to 18 months unlikely.
Locations and Contacts
Princess Marina Hospital, Gaborone, Botswana
Athlone Hospital, Lobatse, Botswana
Scottish Livingstone Hospital, Molepolole, Botswana
Additional Information
Starting date: May 2011
Last updated: June 5, 2015
|